Description

Eterna Peptides presents premium-grade Tirzepatide (GLP-2 Architecture) and BPC-157 lyophilized blend, an advanced dual-action research formulation. Combining a high-capacity dual incretin receptor agonist (60mg) with a stable cytoprotective tissue repair pentadecapeptide (2.6mg) inside a single precise 62.6mg vial, this master synergy serves as an elite investigative tool for tracking concurrent metabolic rate acceleration, adipose tissue repartitioning, and systemic structural cellular repair cascades.

### Advanced 62.6mg Synergistic Blend Profile
Each carefully calibrated vial delivers a precise structural distribution of targeted research compounds:
* **Tirzepatide / GLP-2 Architecture (60mg):** A synthetically structured 39-amino-acid peptide analogue that functions as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Modeled after the endogenous GIP sequence, it features a custom C20 fatty diacid moiety that facilitates stable albumin binding to drastically extend its research half-life, allowing intensive tracking of glycemic stability and lipid oxidation ($ \beta\text{-oxidation} $).
* **BPC-157 (2.6mg – Body Protection Compound):** A stable synthetic pentadecapeptide derived from human gastric juice protein sequences. BPC-157 is intensively investigated for its profound systemic cytoprotective properties, localized expression of vascular endothelial growth factor receptors (such as VEGFR2), and its ability to accelerate the healing kinetics of mucosal linings, muscles, tendons, and ligaments.

### Mechanism of Action
The Tirzepatide / BPC-157 matrix operates via overlapping biological pathways to explore advanced metabolic and tissue-level recovery:
* **Synergistic Incretin Activation:** Tirzepatide activates both native GIP and GLP-1 receptor pathways, driving intracellular cyclic AMP ($cAMP$) accumulation to study optimal pancreatic beta-cell insulin secretion dynamics and white adipose tissue repartitioning.
* **Hypothalamic Satiety & Gastric Emptying Kinetics:** The structural configuration crosses blood-brain barrier boundaries to interface with satiety pathways in the arcuate nucleus, signaling a down-regulation of food-seeking behaviors while de-accelerating upper gastrointestinal motility to study localized nutrient transit feedback loops.
* **Angiogenesis & Tissue Remodeling:** BPC-157 works downstream to upregulate growth factor signaling, establishing new capillary networks (angiogenesis) and promoting proper collagen type-I synthesis. This allows researchers to study accelerated musculoskeletal recovery and mucosal barrier stabilization during intensive metabolic shifts.

### Research Applications
In preclinical and in vitro laboratory models, Tirzepatide / BPC-157 blend vials are actively utilized to investigate:
* High-velocity lipid mobilization, adipose tissue browning kinetics, and structural lean tissue retention during caloric deficit models.
* Accelerated soft tissue wound healing, collagen cross-linking kinetics, and gastrointestinal mucosal lining stabilization.
* Central nervous system satiety pathways, arcuate nucleus neuroplasticity, and behavioral food-seeking motivation curves.
* The comparative baseline potency, multi-receptor affinity curves, and cellular protection of combining metabolic agonists with systemic cytoprotective peptides.

Our blend vials undergo strict laboratory stabilization, purification, and uniform vacuum-drying guidelines to ensure an exact 60mg:2.6mg ratio, absolute peptide chain integrity, rapid reconstitution kinetics, and dependable experimental reproducibility.

—
*Disclaimer: This product is sold strictly for laboratory research and development use only. It is not intended for human consumption, diagnostic, or therapeutic purposes.*